National Cancer Institute (NCI)

335 Protocols (219 Active Accrual of new subjects, 116 Follow-up of previously enrolled subjects)

 09-C-0057:

A Phase II Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma

 09-C-0054:

A Group Wide Biology and Banking Study for Phase II Study of R1507

 09-C-0053:

Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)

 09-C-0052:

Informed Consent in Pediatric Phase I Cancer Trials

 09-C-0051:

Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines

 09-C-0048:

A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

 09-C-0047:

Phase II Study of Metastatic Cancer that Expresses Carcinoembryonic Antigen (CEA) using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes

 09-C-0043:

A Single-dose Study Evaluating the Oral Bioavailability and Pharmacokinetics of the Capsule Formulation of ABT-263 in Subjects with Cancer

 09-C-0041:

Phase I/II Study of Metastatic Cancer that Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes

 09-C-0037:

A Phase II Clinical Trial of Ixabepilone (Ixempra, BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer

 09-C-0025:

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

 09-C-0024:

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults

 09-C-0019:

A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors

 09-C-0018:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Adults with Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Two or More Prior Treatment Regimens

 09-C-0005:

Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease

 09-C-0003:

A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Adults with Advanced Malignancies and Varying Degrees of Liver Dysfunction

 08-C-0226:

A Pilot Study of 11C-Acetate Positron Emission Tomography (PET) and 3 Telsa Magnetic Resonance Imaging (MRI) in Men with Prostate Cancer Undergoing Prostatectomy

 08-C-0223:

ADVL08N1: A Pharmacokinetic Participation Questionnaire Study

 08-C-0214:

A Pilot Study to Evaluate Neuropsychological Outcome Measures and Their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases

 08-C-0208:

Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer

 08-C-0200:

A Pilot Study of 18F Fluorothymidine (FLT) PET/CT in Lymphoma

 08-C-0180:

Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

 08-C-0179:

A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children with Refractory Solid Tumors

 08-C-0176:

First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Etoposide, Doxorubicin, Cisplatin and Mitotane vs Streptozotocin and Mitotane

 08-C-0168:

A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas

 08-C-0166:

An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults with Non-Small Cell Lung Cancer (NSCLC)

 08-C-0164:

A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-cell Lymphoma Following Prior Systemic Therapy

 08-C-0162:

Transfer of Autologous T Cells Transduced with the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma

 08-C-0155:

Phase II Study of Metastatic Cancer that Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination

 08-C-0151:

A Pilot Study of Sirolimus (Rapamycin, Rapammune[Registered Trademark]) in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

 08-C-0130:

A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas

 08-C-0128:

A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors

 08-C-0123:

A Phase 1, Single Center, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (pALL) or Non-Hodgkin's Lymphoma (NHL)

 08-C-0121:

Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes

 08-C-0105:

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

 08-C-0101:

A Phase 2 Trial of Tandutinib in Combination with Bevacizumab for Patients with Recurrent High-Grade Gliomas

 08-C-0097:

Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults

 08-C-0096:

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas

 08-C-0092:

A Phase I Study with an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined with Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers and Familial Breast and Ovarian Cancer

 08-C-0091:

Phase I Study of SNX-5422 Mesylate in Adults with Refractory Solid Tumor Malignancies and Lymphomas

 08-C-0088:

Low Intensity Allogeneic Hematopietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells

 08-C-0087:

Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults with Solid Tumors and Lymphomas

 08-C-0086:

A Phase 2, Open-Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients with Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regime and Failure of Prior Treatment with Erlotinib

 08-C-0083:

Registration Ph III Study of Lucanix ™ (Trademark) in Adv NSC Lung Cancer: An Intl Mltctr RDBPC Study of Lucanix™ (Trademark) Maint Ther for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Dx Following One Reg of Front-line, P

 08-C-0080:

SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the IGF-1 Receptor for the Treatment of Patients with Recurrent or Refractory Ewing's Sarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas

 08-C-0079:

Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1

 08-C-0078:

A Phase I/II trial of Pemetrexed (Alimta [Registered Trademark]) Combined with Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects with Relapsed or Refractory NSCLC Whose Tumors Bear Activation of mTOR

 08-C-0077:

A Phase I, Multi-Institutional, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects with Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Tx

 08-C-0074:

A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)

 08-C-0071:

Phase I Study of Bortezomib and Cetuximab without or with Cisplatin in Combination with Radiation Therapy for Advanced Head and Neck Cancer

 08-C-0051:

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies

 08-C-0039:

A Phase II Study of ZD6474 (Vandetanib) in Subjects with Advanced Clear Cell Renal Carcinoma

 08-C-0035:

A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1® (Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues

 08-C-0033:

Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma

 08-C-0030:

Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas

 08-C-0026:

A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma

 08-C-0020:

A Phase 2 Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal Tumors

 08-C-0015:

A Phase II Trial of Enzastaurin (LY317615) in Combination with Bevacizumab in Adults with Recurrent Malignant Gliomas

 08-C-0010:

Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors

 08-C-0007:

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer

 07-C-0230:

A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases

 07-C-0228:

Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction

 07-C-0220:

A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors

 07-C-0210:

Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma

 07-C-0206:

A Pilot Study of Tumor Vaccination in Patients with High Risk Pediatric Solid Tumors and Altered T Cell Homeostasis

 07-C-0203:

A Phase I Study of ABT-888 in Combination with Topotecan Hydrochloride in Adults with Refractory Solid Tumors and Lymphomas

 07-C-0195:

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors and Utilizing Two Graft-Versus-Host Disease Prophylaxis Regimens

 07-C-0189:

Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma

 07-C-0188:

A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men with D0 Prostate Cancer Following Limited Androgen Ablation

 07-C-0176:

A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma

 07-C-0175:

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes

 07-C-0174:

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes

 07-C-0166:

A Phase I Study of BMS-354825 (DASATINIB) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistent PH Plus Leukemia

 07-C-0133:

Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma

 07-C-0130:

A Phase 1, Multicenter, Dose-Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL)

 07-C-0123:

Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer

 07-C-0121:

A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma (PRC)

 07-C-0114:

A Phase I Study of Subcutaneous CYT 107 (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma

 07-C-0111:

A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies

 07-C-0110:

Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols

 07-C-0107:

A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men with Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer

 07-C-0106:

A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) with or without a PSA/TRICOM Vaccine in Men with Androgen-Insensitive Metastatic Prostate Cancer

 07-C-0101:

A Phase 0 Trial of (111)Indium CHX-A" DTPA trastuzumab Imaging in Cancer

 07-C-0100:

Collection of Blood from Patients with Prostate Cancer

 07-C-0097:

A Phase I Study of Batracylin (NSC320846) in Subjects with Solid Tumors and Lymphomas

 07-C-0087:

A Natural History Study of HIV Acquired in Infancy or Childhood

 07-C-0086:

Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures

 07-C-0085:

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults with Metastatic, Recurrent, or Progressive Cancer or HIV Disease

 07-C-0081:

A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

 07-C-0074:

A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children with Relapsed or Refractory Neuroblastoma

 07-C-0064:

Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation with Costimulated, Tumor-Derived Lymphocytes

 07-C-0059:

A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer

 07-C-0058:

A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer

 07-C-0054:

A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS [R], ET-743) in Children and Adolescents with Relapsed or Refractory Solid Tumors

 07-C-0053:

A Phase I Trial of Enzastaurin (LY317615) in Combination with Carboplatin in Adults with Recurrent Gliomas

 07-C-0047:

A Phase I Trial of Nelfinavir (Viracept) in Adults with Solid Tumors

 07-C-0040:

A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors

 07-C-0006:

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies

 06-C-0250:

A Phase II Trial of Bevacizumab and Irinotecan for Patients with Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)

 06-C-0233:

A Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias

Next 100 Protocols

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/13/2009